NeuroSense Therapeutics Ltd - Warrants (09/11/2026) Return on Equity

NeuroSense Therapeutics Ltd - Warrants (09/11/2026) (NRSNW) currently reports a ROE of 713.14%. That is above the sector sector average of -5.84%. Use the charts on this page to explore NeuroSense Therapeutics Ltd - Warrants (09/11/2026)'s ROE history and peer comparisons.

NeuroSense Therapeutics Ltd - Warrants (09/11/2026)'s ROE of 713.14% is higher than the its sector sector average of -5.84%. That is roughly 12301.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but NeuroSense Therapeutics Ltd - Warrants (09/11/2026)'s current 713.14% should be judged against industry norms (sector average: -5.84%) and against NRSNW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 713.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.84%. From there, open related valuation or income-statement pages for NeuroSense Therapeutics Ltd - Warrants (09/11/2026), and consider following NRSNW for alerts when major investors trade the stock.